Related Experiment Video
Updated: Apr 17, 2026

09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
12.8K
Selective Intra-Arterial Cooling Infusion with Endovascular Thrombectomy for Acute Ischemic Stroke: A Multicenter,
Ruiwen Che1, Guang Zhang2, Lan Liu3,4,5
1Department of Neurology and Psychiatry, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Cerebrovascular Diseases (Basel, Switzerland)
|April 15, 2026
Summary
Selective intra-arterial cooling infusion (SI-AC) combined with endovascular thrombectomy (EVT) may improve outcomes for acute ischemic stroke (AIS) patients. This trial evaluates SI-AC
Area of Science:
- Neurology
- Cardiovascular Medicine
- Interventional Radiology
Background:
- Acute ischemic stroke (AIS) from large-vessel occlusion (LVO) requires timely intervention.
- Endovascular thrombectomy (EVT) is a standard treatment for LVO-AIS.
- Cerebroprotective strategies, like hypothermia, are being investigated to improve EVT outcomes.
Purpose of the Study:
- To determine the efficacy and safety of selective intra-arterial cooling infusion (SI-AC) as an adjunct to EVT in patients with anterior circulation LVO-AIS.
- To assess if SI-AC improves functional recovery compared to EVT alone.
Main Methods:
- A multicenter, randomized, controlled, blinded superiority trial involving 12 hospitals in China.
- Patients with anterior circulation LVO-AIS within 24 hours of symptom onset were randomized 1:1 to receive SI-AC plus EVT or EVT alone.
- Follow-up was conducted for 90 days, with functional recovery assessed using the modified Rankin Scale (mRS).
Main Results:
- The primary outcome is the distribution of mRS scores at 90 days.
- Secondary outcomes include functional independence (mRS 0-2), good outcome (mRS 0-1), Barthel index, infarct volume, and early neurological improvement.
- Safety outcomes include intracranial hemorrhage and all-cause mortality.
Conclusions:
- This trial is designed to evaluate the efficacy and safety of SI-AC as a novel cerebroprotective strategy.
- The results will inform the potential use of SI-AC in clinical practice for LVO-AIS patients undergoing EVT.

